Welcome to our dedicated page for Anterix SEC filings (Ticker: ATEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the revenue impact of a new 900 MHz lease or tracking when Anterix executives buy shares often means sorting through hundreds of pages of technical jargon. Stock Titan’s AI-powered analysis turns those dense SEC filings into clear answers in minutes.
Browse every ATEX submission—annual report 10-K, quarterly earnings report 10-Q, 8-K material events, proxy statement executive compensation, and Anterix insider trading Form 4 transactions—with real-time alerts as each document hits EDGAR. Our engine highlights spectrum-license revenue trends, utility contract amendments, and risk factors tied to private LTE deployments, then explains them in straightforward language so you can focus on decisions, not decoding.
Common investor questions are addressed right on the page: “Where can I read the latest Anterix quarterly earnings report 10-Q filing?” or “How do I monitor Anterix executive stock transactions Form 4 in real time?” One click surfaces AI summaries that spotlight cash-flow timing on long-term leases, capital needs for network build-outs, and board updates on cybersecurity. Need quick context on a sudden 8-K? Our tool links the filing to market-moving details and offers plain-English guidance.
Whether you’re comparing insider selling patterns, dissecting spectrum valuation, or understanding Anterix SEC documents with AI, Stock Titan delivers the depth professionals expect without the usual time sink.
Anterix Inc. (ATEX) Chief Legal Officer and Corporate Secretary Gena L. Ashe reported a stock sale in a Form 4 filing. On 11/18/2025, she sold 6,564 shares of Anterix common stock at a price of $21.07 per share. After this transaction, she beneficially owns 13,366 shares of Anterix common stock directly.
Anterix Inc. reported a sharp turnaround to profitability for the quarter ended September 30, 2025. Net income was $53.5 million versus a $12.8 million loss a year ago, driven primarily by a $59.6 million non‑monetary gain from exchanging narrowband spectrum for broadband licenses and an $11.5 million gain on spectrum sales. Spectrum revenue was $1.6 million, essentially flat year over year.
Total assets rose to $420.4 million, including $325.3 million of intangible assets tied to spectrum. Deferred revenue reached $130.4 million, reflecting customer prepayments to be recognized over time, and remaining performance obligations were $178.5 million. Cash and cash equivalents were $39.1 million, with operating cash outflow of $1.7 million in the first half as gains were largely non‑cash.
The company advanced commercial deliveries, including transfers to LCRA and Oncor, and continued spectrum clearing and license exchanges. Operating expenses declined on lower G&A and product development costs, partially offset by severance related to workforce reductions.
Anterix Inc. (ATEX) disclosed insider equity activity by its CFO. On 09/29/2025, the officer received 11,405 restricted stock units. The grant vests 1/3 on September 29, 2026, with the remainder vesting in two equal annual installments thereafter.
On 10/04/2025, 404 shares were withheld at $22.55 to satisfy tax obligations tied to a partial RSU vest and settlement. Following these transactions, the officer directly owned 18,029 common shares.
Anterix Inc. (ATEX)7,028 shares of common stock, which include Restricted Stock Units: 877 shares vesting on May 15, 2026; 672 shares vesting on July 12, 2026; and 3,925 shares vesting in three equal annual installments beginning October 4, 2025.
The filing also lists a stock option for 3,680 shares at an exercise price of $40, expiring on 04/03/2035, vesting in three equal annual installments beginning October 4, 2025.
Anterix Inc. (ATEX) reported an initial statement of beneficial ownership. A company officer filed Form 3 effective 09/17/2025, disclosing 34,578 shares of common stock held directly. The filer is identified as an Officer (Chief Marketing Officer) and Chief of Staff. The filing also notes Restricted Stock Units that will vest in three equal installments beginning on September 9, 2026.
Anterix Inc. disclosed that on
Lang Scott A., President, CEO and Director of Anterix Inc. (ATEX), reported a personal purchase of company stock. On 09/18/2025 he acquired 4,650 shares of Common Stock at $21.28 per share and after the transaction beneficially owned 4,650 shares directly. The Form 4 was filed by one reporting person and was signed by an attorney-in-fact on the same date.
Anterix, Inc. (ATEX) disclosed a Chief Financial Officer transition: Timothy A. Gray resigned as CFO effective September 19, 2025, and the Board appointed Elena Marquez as CFO effective September 22, 2025. Ms. Marquez, age 39, has served as Vice President of Finance and Controller since September 2021 and previously held senior finance roles at Clinical Genomics and Prudential Financial. In connection with her promotion, she will receive additional restricted stock units with an aggregate grant date fair value of $250,000 vesting in three equal annual installments and will be eligible to participate in the Company’s Executive Severance Plan. The Board designated her as the company’s principal financial officer and principal accounting officer for SEC purposes. The filing notes standard indemnification and states there are no related-party or Item 404 transactions to disclose.
Insider transaction summary: Anterix Inc. (ATEX) Chief Financial Officer Timothy Gray reported a purchase of 50 shares of the issuer's common stock on 08/19/2025 at a price of $22.07 per share. Following the purchase, Mr. Gray beneficially owns 77,022 shares in a direct capacity. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
FAQ
What is the current stock price of Anterix (ATEX)?
What is the market cap of Anterix (ATEX)?
